Document:

Exhibit 10.3 

LEAK-OUT AGREEMENT

 

April 7, 2020

 

This agreement (the
“Leak-Out Agreement”) is being delivered to you by the undersigned shareholder of the Company (the “Shareholder”)
in connection with an understanding by and between AgEagle Aerial Systems, Inc., a Nevada corporation (the “Company”),
and Alpha Capital Anstalt or its assigns (the “Holder”).

 

Reference is hereby
made to (a) the Securities Purchase Agreement, dated April 7, 2020 (the “Purchase Agreement”), by and between
the Company and the Holder pursuant to which the Holder acquired shares (“Shares”) of Series E Preferred Stock
of the Company. Capitalized terms used herein but not defined herein shall have the meaning as set forth in the Purchase Agreement.
The Company, as a condition to the Holder’s purchase of the Shares, is requiring this Leak-Out Agreement from all record and beneficial
owners of 5% or more of the Company’s common stock or convertible equivalents.

 

The Shareholder
agrees with the Company and the Holder that, for a period of seven (7) months from the date hereof (such period, the “Restricted
Period”), neither the Shareholder, nor any Affiliate of the Shareholder which has or shares discretion relating to the
Shareholder’s investments or trading or information concerning the Shareholder’s investments, including in respect of the shares
of common stock (together, the “Shareholder’s Trading Affiliates”), collectively, shall not sell, dispose or otherwise
transfer, directly or indirectly, (including, without limitation, any sales, short sales, swaps or any derivative transactions
that would be equivalent to any sales or short positions) any shares of Common Stock, or shares of Common Stock underlying any
Common Stock Equivalents held by the Shareholder on the date hereof (collectively, the “Restricted Securities”);
and after the expiration of such seven (7) month lockup, shall not sell dispose or otherwise transfer, directly or indirectly,
including, without limitation, any sales, short sales, swaps or any derivative transactions that would be equivalent to any sales
or short positions in an amount representing more than $25,000 per calendar month of shares of Common Stock (“Leak-Out
Percentage”) for a period of six (6) months thereafter (the “Leak-Out Period”), after which time, the
restrictions set forth in this Leak-Out Agreement shall cease.

 

Notwithstanding
anything herein to the contrary, during the Restricted Period and the Leak-Out Period, the Shareholder may, directly or indirectly,
sell or transfer all, or any part, of the Restricted Securities to any Person (an “Assignee”) in a transaction
which does not need to be reported on the NYSE American consolidated tape, without complying with (or otherwise limited by) the
restrictions set forth in this Leak-Out Agreement; provided that, as a condition to any such sale or transfer an authorized signatory
of the Company and such Assignee duly execute and deliver a leak-out agreement in the form of this Leak-Out Agreement (an “Assignee
Agreement”, and each such transfer a “Permitted Transfer”) and, subsequent to a Permitted Transfer, sales
of the Shareholder and the Shareholder r’s Trading Affiliates and all Assignees (other than any such sales that constitute Permitted
Transfers) shall be aggregated for all purposes of this Leak-Out Agreement and all Assignee Agreements.

 

     

     

    

 

Any notices, consents,
waivers or other communications required or permitted to be given under the terms of this Leak-Out Agreement must be in writing
and shall be given in accordance with the terms of the Purchase Agreement, provided that, with respect to any notices, consents,
waivers or other communications to be made by the Company to the Shareholder, such notice, consent, waiver or other communication
shall be delivered to the Shareholder at the e-mail address or facsimile number on the signature page hereto.

 

This Leak-Out Agreement
constitutes the entire agreement among the parties hereto with respect to the subject matter hereof and supersedes all prior negotiations,
letters and understandings relating to the subject matter hereof and are fully binding on the parties hereto.

 

This Leak-Out Agreement
may be executed simultaneously in any number of counterparts. Each counterpart shall be deemed to be an original, and all such
counterparts shall constitute one and the same instrument. This Leak-Out Agreement may be executed and accepted by facsimile or
PDF signature and any such signature shall be of the same force and effect as an original signature.

 

The terms of this
Leak-Out Agreement shall be binding upon and shall inure to the benefit of each of the parties hereto and their respective successors
and assigns.

 

This Leak-Out Agreement
may not be amended or modified except in writing signed by each of the parties hereto, including the Holder.

 

All questions concerning
the construction, validity, enforcement and interpretation of this Leak-Out Agreement shall be governed by the applicable provisions
of the Purchase Agreement.

 

Each party hereto
acknowledges that, in view of the uniqueness of the transactions contemplated by this Leak-Out Agreement, the other party or parties
hereto will not have an adequate remedy at law for money damages in the event that this Leak-Out Agreement has not been performed
in accordance with its terms, and therefore agrees that such other party or parties, including, without limitation, the Holder,
shall be entitled to seek specific enforcement of the terms hereof in addition to any other remedy it may seek, at law or in equity.

 

    2 

     

    

 

The obligations
of the Shareholder under this Leak-Out Agreement are several and not joint with the obligations of any other signatory under any
other similar agreement, and the Shareholder shall not be responsible in any way for the performance of the obligations of any
other person under any such other agreement. Nothing contained in this Leak-Out Agreement, and no action taken by the Holder or
the Company pursuant hereto, shall be deemed to constitute the Holder and the Shareholder as a partnership, an association, a joint
venture or any other kind of entity, or create a presumption that the Holder and the Company or the Shareholder are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by this Leak-Out Agreement and
the Company acknowledges that the Holder and the Shareholder are not acting in concert or as a group with respect to such obligations
or the transactions contemplated by this Leak-Out Agreement or any other agreement. The Company and the Shareholder confirm that
the Shareholder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its
own counsel and advisors.

 

[The remainder of the page is intentionally
left blank]

 

    3 

     

    

 

The parties hereto have executed this UAVS Leak-Out Agreement
as of the date first set forth above.

 

	 	Sincerely,
	 	 	 
	 	AgEagle
Aerial Systems, Inc.
	 	 	 
	 	By:	/s/ Nicole Fernandez McGovern
	 	 	Name: Nicole Fernandez
McGovern
	 	 	Title: Chief Financial
Officer

 

Agreed to and Acknowledged:

 

“SHAREHOLDER”

 

	By:	/s/ Bret
    Chilcott	 
	 	 	 
	 	Name: Bret Chilcott	 
	 	Title: AgEagle Founder	 
	 	Email Address: BretChilcott@gmail.com BretC@AgEagle.com

 

Agreed to acknowledged:

 

“HOLDER”

 

Alpha Capital Anstalt

 

	By:	/s/ Nicola Feuerstein	 
	 	Name: Nicola Feuerstein	 
	 	Title: Secretary	 
	 	Email :

 

[Signature Page to UAVS Leakout]EX-10.1

 Exhibit 10.1 

SEPARATION AGREEMENT 

This Separation Agreement (this “Agreement”) by and between Michael MacLean (“Employee”) and
Akcea Therapeutics, Inc., a Delaware corporation (the “Company”), is made and entered into as of April 2, 2020 (the “Execution Date”) and is effective eight (8) days thereafter (the
“Effective Date”), unless Employee rescinds his acceptance of this Agreement as provided in Section 5 below, with reference to the following facts: 

The Company and Employee are parties to the Retention Letter between Company and Employee, dated October 11, 2019 (the
“Retention Letter”) and the Severance and Equity Award Vesting Acceleration Letter dated November 28, 2017 (the “Severance Letter”); 

Executive signed an Employee Confidential Information, Inventions Assignment, Non-Competition and Non-Solicitation Agreement with the Company dated November 28, 2017 (the “Non-Competition Agreement”), which contains certain restrictive
covenants, applicable before and after the term of his employment with the Company, including a non-competition and non-solicitation covenant and a covenant against the
disclosure of confidential information of the Company; 
 The Employee’s employment with the Company shall terminate effective as of
April 1, 2020 (the “Separation Date”), subject to the terms and conditions set forth in this Agreement; and 

The Employee and Company desire to enter into this Agreement to memorialize the terms and conditions of Employee’s separation from the
Company; 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, the parties hereby agree as follows:

 1.    Separation Date. Employee’s employment with the Company shall end on the Separation Date. Following
the Separation Date, Employee shall not be and shall not represent himself as an employee or agent of the Company. As of the Execution Date, Employee shall be deemed to have resigned (and hereby memorializes such resignation) from each and every
other office, position or responsibility in, including as a director and officer of the Company, in which Employee served for the Company and/or Ionis Pharmaceuticals, Inc. (“Ionis”) and each of their respective affiliates,
subsidiaries and divisions. 
 2.    Final Paycheck; Payment of Accrued Wages and Expenses. 

(a)    Final Paycheck. On the Separation Date, the Company will pay Employee all accrued but unpaid base salary and
all accrued and unused vacation earned through the Separation Date, subject to standard payroll deductions and withholdings. Employee is entitled to these payments regardless of whether Employee executes this Agreement. 

(b)    Business Expenses. The Company shall reimburse Employee for all outstanding expenses incurred on or prior to
the Separation Date which are consistent with the Company’s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company’s requirements with respect to reporting and
documenting such expenses. 

 3.    Separation Payments and Benefits. Without admission of any
liability, fact or claim, the Company hereby agrees, subject to this Agreement becoming effective and irrevocable, as well as Employee’s performance of his continuing obligations pursuant to this Agreement, to provide Employee the severance
benefits set forth below (the “Separation Benefit”). Specifically, the Company and Employee agree as follows: 

(a)    Severance. The Company shall pay to Employee on the first business day after the end of the six-month period following the Separation Date, a lump sum payment in an amount equal to Four Hundred Thirty Eight Thousand One Hundred Sixty One Dollars ($438,161), which represents twelve (12) months of
Employee’s annual base salary at the rate in effect immediately prior to the Separation Date. 
 (b)    10b5-1 Plans. Within five business days after the Effective Date, the Company will terminate Employee’s Akcea Therapeutics, Inc. 10B5-1 Trading Plan(s) and will
direct its stock plan administrator to remove any restrictions on Employee’s trading accounts to enable Employee to trade the Company’s stock in Employee’s sole discretion. Employee acknowledges and agrees that he will only trade in
the Company’s stock at such times as Employee is not in possession of material, non-public information regarding the Company. 

(c)    Healthcare Continuation Coverage. If Employee timely elects to receive continued healthcare coverage
(health, dental and vision) pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall directly pay, or reimburse, Employee’s COBRA premiums,
and any applicable Company COBRA premiums necessary to continue Employee’s coverage as in effect on the Separation Date, such payment or reimbursement to continue until the earlier of (i) the last day of the twelfth (12th) month anniversary following the Separation Date; or (ii) the date Employee first becomes eligible after the Separation Date to enroll in a group health insurance plan offered by another
employer or entity in connection with Employee’s provision of services to such employer or entity. Employee agrees to immediately notify the Company in writing of any such enrollment or eligibility for enrollment and the Company’s
obligations to pay any COBRA premiums for all periods after the effective date of such enrollment or eligibility will cease. Except as provided in this Agreement, Employee acknowledges that he shall be solely responsible for all matters relating to
Employee’s continuation of coverage pursuant to COBRA, including, without limitation, Employee’s election of such coverage and his timely payment of his share of the applicable premiums. 

(d)    Taxes. Employee understands and agrees that all payments under this Section 3 will be subject to
appropriate tax withholding and other deductions. To the extent any taxes may be payable by Employee for the benefits provided to him by this Section 3 beyond those withheld by the Company (including taxes withheld under Section 3(b)),
Employee agrees to pay them himself and to indemnify and hold the Company and the other entities released herein harmless for any tax claims or penalties, and associated attorneys’ fees and costs, resulting from any failure by him to make his
required payments. 

 The terms of this Agreement shall be construed and administered in a manner calculated to
satisfy the short-term deferral exception under Treas. Reg. Section 1.409A-1(b) (4); the separation pay plan exception under Treas. Reg.
Section 1.409A-1(b)(9)(iii); and/or the welfare benefit exception under Treas. Reg. 1.409A-1(b)(9)(v) to Internal Revenue Code Section 409A and the applicable
regulations and guidance promulgated thereunder (“Section 409A”). Any reference in this Agreement to a separation from or termination of employment (or similar term) means a
“separation from service” as defined in Section 409A and the applicable guidance issued thereunder. If and to the extent that this Agreement fails to satisfy an exception to Section 409A, it will be construed and
administered in accordance therewith to the maximum extent permitted by law. If payment of any amount subject to Section 409A is triggered by a separation from service that occurs while Employee is a “specified employee” (as
defined by Section 409A) with, and if such amount is scheduled to be paid within six (6) months after such separation from service, the amount shall accrue without interest and shall be paid the first business day after the end of such six-month period, or, if earlier, within 15 days after the appointment of the personal representative or executor of Employee’s estate following his death. All rights to payments and benefits hereunder shall be
treated as rights to receive a series of separate payments and benefits for purposes of applying Section 409A. If any payment subject to Section 409A is contingent on the delivery of a release by Employee and could occur in either of two
years, the payment will occur in the later year. Nothing in this Agreement shall be construed as a guarantee of any particular tax treatment to Employee. Employee shall be solely responsible for the tax consequences with respect to all amounts
payable under this Agreement, and in no event shall the Company have any responsibility or liability if this Agreement does not meet any applicable requirements of Section 409A. 

(e)    Sole Separation Benefit. Employee agrees that the payments provided by this Section 3 are not required
under the Company’s normal policies and procedures and are provided as a severance solely in connection with this Agreement. Employee acknowledges and agrees that the payments referenced in this Section 3 constitute adequate and valuable
consideration, in and of themselves, for the promises contained in this Agreement. Employee acknowledges and agrees that the Separation Benefit is not intended to and does not constitute a severance plan or confer a benefit on anyone other than the
parties. 
 4.    Full Payment. Employee acknowledges that the payment and arrangements herein shall constitute
full and complete satisfaction of any and all amounts properly due and owing to Employee as a result of his employment with the Company and the termination thereof, including, but not limited to, salary, wages, bonuses, accrued vacation/paid time
off, notice periods, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses, commissions, stock, additional stock options, vesting, and any and all other benefits and compensation
due to Employee. For purposes of clarity, subject to the terms of the applicable Company equity plans and the equity agreements between the Company and Employee (the “Equity Agreements”), Employee retains his rights to any
and all of his vested stock options, vested restricted stock units and vested common stock held by Employee as of the Separation Date (collectively, “Vested Equity”). 

5.    Employee’s Release of Claims. Employee hereby agrees and acknowledges that by signing this Agreement and
accepting the severance payments to be provided to him, and other good and valuable consideration provided for in this Agreement, Employee is waiving his right to 

 
assert any form of legal claim against the Company1 of any kind whatsoever from the beginning of time through the Effective Date.
Employee’s waiver and release herein is intended to bar any form of legal claim, charge, complaint or any other form of action (jointly referred to as “Claims”) against the Company seeking any form of relief including,
without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages or any other form of monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional
distress damages, punitive damages, attorneys’ fees and any other costs) against the Company, up through the Effective Date. 
 Without
limiting the foregoing general waiver and release of claims, Employee specifically waives and releases the Company from any Claim arising from or related to Employee’s employment relationship with the Company or the termination thereof,
including, without limitation: 
 (i)    Claims under any state or federal discrimination, fair
employment practices or other employment related statute, regulation or executive order (as they may have been amended through the Effective Date) prohibiting discrimination or harassment based upon any protected status including, without
limitation, race, national origin, age, gender, marital status, disability, veteran status or sexual orientation. Without limitation, specifically included in this paragraph are any Claims arising under the federal Age Discrimination in Employment
Act, the Older Workers Benefit Protection Act, the Civil Rights Acts of 1866 and 1871, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Equal Pay Act, the Americans With Disabilities Act and any similar Massachusetts or
other state statute. 
 (ii)    Claims under any other state or federal employment related statute,
regulation or executive order (as they may have been amended through the Effective Date) relating to wages, hours or any other terms and conditions of employment. Without limitation, specifically included in this paragraph are any Claims arising
under the Fair Labor Standards Act, the Family and Medical Leave Act of 1993, the National Labor Relations Act, the Employee Retirement Income Security Act of 1974, the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA) and any similar
Massachusetts or other state statute. 
 (iii)    Claims under any state or federal common law theory
including, without limitation, wrongful discharge, breach of express or implied contract, promissory estoppel, unjust enrichment, breach of a covenant of good faith and fair dealing, violation of public policy, defamation, interference with
contractual relations, intentional or negligent infliction of emotional distress, invasion of privacy, misrepresentation, deceit, fraud or negligence. 

 

	1 	 For purposes of this release of claims, the term “Company” shall include Akcea Therapeutics, Inc. and
its divisions, affiliates, parents and subsidiaries, and their respective officers, directors, shareholders, owners, employees and assigns. 

 (iv)    Any other Claim arising under state or federal
law. 
 Notwithstanding the foregoing, this Section shall not release the Company from any obligation expressly set forth in this Agreement,
nor is Employee releasing any claims to vested benefits (e.g., Employee’s vested 401(k) balance), his rights to his Vested Equity and/ or to any rights to indemnification that Employee may have pursuant to insurance policy, Company by-law, charter or operating agreement, and/or applicable law. 
 Employee and the Company acknowledge
that Employee is over the age of 40 and that Employee, therefore, has specific rights under the Age Discrimination in Employment Act (“ADEA”) and the Older Workers Benefit Protection Act (the “OWBPA”),
which prohibit discrimination on the basis of age. It is the Company’s desire and intent to make certain that Employee fully understands the provisions and effects of this Agreement, which includes a release of claims under the ADEA and OWBPA.
To that end, Employee has been encouraged and given the opportunity to consult with legal counsel for the purpose of reviewing the terms of this Agreement. Consistent with the provisions of the ADEA and OWBPA, the Company also is providing Employee
with twenty-one (21) days in which to consider and accept the terms of this Agreement by signing below and returning it to the Company at the address below. Employee may rescind his assent to this
Agreement if, within seven (7) days after Employee signs this Agreement, Employee delivers by hand or sends by mail (certified, return receipt and postmarked within such seven (7) day period) a notice of rescission to the Company at 22
Boston Wharf Road, 9th Floor, Boston, MA 02210. 
 Also, consistent with the provisions
of the ADEA, nothing in this release shall be deemed to prohibit Employee from challenging the validity of this release. Employee understands that nothing in this Agreement shall in any way limit or prohibit Employee from engaging for a lawful
purpose in any Protected Activity, provided, however, that Employee agrees not to seek or accept any monetary award from such a proceeding (except with respect to proceedings before the Securities and Exchange Commission). For purposes of
this Agreement, “Protected Activity” shall mean filing a charge, complaint, or report with, or otherwise communicating with, cooperating with or participating in any investigation or proceeding that may be conducted by, any
federal, state or local government agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board
(“Government Agencies”). Employee understands that in connection with such Protected Activity, Employee is permitted to disclose documents or other information as permitted by law, and without giving notice to, or receiving
authorization from, the Company. Notwithstanding the foregoing, Employee agrees to take all reasonable precautions to prevent any unauthorized use or disclosure of any information that may constitute Company confidential information to any parties
other than the relevant Government Agencies. Employee further understands that “Protected Activity” does not include the disclosure of any Company attorney-client privileged communications, and that any such disclosure without the
Company’s written consent shall constitute a material breach of this Agreement. In addition, pursuant to the Defend Trade Secrets Act of 2016, Employee is notified that an individual will not be held criminally or civilly liable under any
federal or state trade secret law for the disclosure of a trade secret that (i) is made in confidence to a federal, state, or local government official (directly or indirectly) or to an attorney solely for the purpose of reporting or
investigating a suspected violation of law, or (ii) is made in a complaint or other document filed 

 
in a lawsuit or other proceeding, if (and only if) such filing is made under seal. In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected
violation of law may disclose the trade secret to the individual’s attorney and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal and does not disclose the
trade secret, except pursuant to court order. 
 Employee acknowledges that he has carefully read and understands the scope and effect of
the provisions of this Agreement, has been advised to consult with an attorney and that he has had the opportunity to do so. Employee has not relied upon any representations or statements made by the Company that are not specifically set forth in
this Agreement. 
 Employee acknowledges and agrees that, but for providing this waiver and release of claims, Employee would not be
receiving the severance being provided to him under this Agreement. 

6.    Non-Disparagement, Transition, Transfer of Company Property and Non-Competition Agreement. Both parties further agree that: 
 (a)    Mutual Non-Disparagement. Employee agrees that he will not make any public media statements with respect to the Company without the prior approval of the Company and that he will not disparage or knowingly make false
or defamatory statements about the Company or Ionis, or their respective directors, officers, or affiliates in any manner whatsoever (including through the use of any social networking sites, blogs, forums or any similar medium, including in
response to inquiries from other users of such medium) whether directly or indirectly through a third party. The Company agrees to instruct its senior corporate executives having the position of Vice President or above and the current members of its
Board of Directors not to disparage or knowingly make false or defamatory statements regarding Employee. This Section shall not apply to communications required by law, or that are otherwise privileged as a matter of law. Employee’s non-disparagement obligations under this Section do not interfere with or restrict his ability to communicate with any federal, state, or local agency, including any with which a charge has been filed. 

(b)    Transfer of Company Property. On or before the Separation Date, Employee shall turn over to the Company all
files, memoranda, records, and other documents, and any other physical or personal property which are the property of the Company and which he had in his possession, custody or control at the time he signed this Agreement. 

(c)    Continuation of Non-Competition Agreement Prior Covenants. Employee
acknowledges and agrees that he is bound by and will strictly comply with the terms of the Non-Competition Agreement, including but not limited to the terms of Sections 1,2,7,8 and 15 of the Non-Competition Agreement and all related enforcement provisions which by their terms survive any termination of employment. 

7.    Employee Representations; Company Representations. Employee warrants and represents that (a) he has not
filed or authorized the filing of any complaints, charges or lawsuits against the Company or any affiliate of the Company with any governmental agency or court, and that if, unbeknownst to Employee, such a complaint, charge or lawsuit has been filed
on his behalf, 

 
he will immediately cause it to be withdrawn and dismissed, (b) he has reported all hours worked as of the date of this Agreement and has been paid all compensation, wages, bonuses,
commissions, and/or benefits to which he may be entitled and no other compensation, wages, bonuses, commissions and/or benefits are due to him, except as provided in this Agreement, (c) he has no known workplace injuries or occupational
diseases and has been provided and/or has not been denied any leave requested under the Family and Medical Leave Act or any similar state law, (d) the execution, delivery and performance of this Agreement by Employee does not and will not
conflict with, breach, violate or cause a default under any agreement, contract or instrument to which Employee is a party or any judgment, order or decree to which Employee is subject, and (e) upon the execution and delivery of this Agreement
by the Company and Employee, this Agreement will be a valid and binding obligation of Employee, enforceable in accordance with its terms. The Company represents that it is not aware of any facts or circumstances upon which it intends to assert, or
is actively considering asserting, a claim against Employee arising out of or relating to his employment or the termination of that employment, and (ii) upon the execution and delivery of this Agreement by the Company and Employee, this
Agreement will be a valid and binding obligation of the Company, enforceable in accordance with its terms. 

8.    No Assignment by Employee. Employee warrants and represents that no portion of any of the matters released
herein, and no portion of any recovery or settlement to which Employee might be entitled, has been assigned or transferred to another person, firm or corporation not a party to this Agreement, in any manner, including by way of subrogation or
operation of law or otherwise. If any claim, action, demand or suit should be made or instituted against the Company or any other releasee because of any actual assignment, subrogation or transfer by Employee, Employee agrees to indemnify and hold
harmless the Company and all other releasees against such claim, action, suit or demand, including necessary expenses of investigation, attorneys’ fees and costs. In the event of Employee’s death, this Agreement shall inure to the benefit
of Employee and Employee’s executors, administrators, heirs, distributees, devisees, and legatees. None of Employee’s rights or obligations may be assigned or transferred by Employee, other than Employee’s rights to payments
hereunder, which may be transferred only upon Employee’s death by will or operation of law. 

9.    Confidentiality. Employee and the Company mutually agree to maintain in complete confidence the existence of
this Agreement, the contents and terms of this Agreement, and the consideration for this Agreement (hereinafter collectively referred to as “Separation Information”) provided that nothing herein shall prevent the Company from
meeting its obligations under applicable law or binding agreements. Except as required by law, Employee may disclose Separation Information only to Employee’s immediate family members, the Court in any proceedings to enforce the terms of this
Agreement, bank personnel in connection with a personal loan, the office of unemployment, taxing authorities, Employee’s counsel, and Employee’s accountant and any professional tax advisor to the extent that they need to know the
Separation Information in order to provide advice on tax treatment or to prepare tax returns, and must prevent disclosure of any Separation Information to all other third parties. Employee will not publicize, directly or indirectly, any Separation
Information. 
 10.    Governing Law. This Agreement shall be construed and enforced in accordance with, and the
rights of the parties shall be governed by, the laws of the Commonwealth of 

 
Massachusetts or, where applicable, United States federal law, in each case, without regard to any conflicts of laws provisions or those of any state other than Massachusetts. 

11.    Miscellaneous. Employee further acknowledges that, other than the
Non-Competition Agreement and the Equity Agreements, this Agreement shall supersede each agreement entered into between Employee and the Company regarding Employee’s employment, including, without
limitation, the Retention Letter and the Severance Letter, and each such agreement shall be deemed terminated and of no further effect as of the Separation Date. Employee acknowledges that there are no other agreements, written, oral or implied, and
that he may not rely on any prior negotiations, discussions, representations or agreements. This Agreement may be modified only in writing, and such writing must be signed by both parties and recited that it is intended to modify this Agreement.
This Agreement may be executed in separate counterparts in PDF or other electronic forms, each of which is deemed to be an original and all of which taken together constitute one and the same agreement. 

12.    Company Assignment and Successors. The Company shall assign its rights and obligations under this Agreement
to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise). This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns, personnel and legal
representatives. 
 13.    Employee’s Cooperation. After the Separation Date, Employee shall use reasonable
best efforts to cooperate with the Company and its affiliates, upon the Company’s reasonable request, with respect to any internal investigation or administrative, regulatory or judicial proceeding involving matters within the scope of
Employee’s duties and responsibilities to the Company or its affiliates during his employment with the Company. The Company will reimburse Employee for the reasonable expenses he incurs to comply with this provision. 

(Signature page(s) follow) 

 IN WITNESS WHEREOF, the undersigned have caused this Separation Agreement to be duly
executed and delivered as of the date indicated next to their respective signatures below. 
  

							
		 		 	EMPLOYEE
				
	DATED: April 4, 2020                    	 		 	By:	 	/s/ Michael MacLean
		 		 	Name:	 	Michael MacLean

  
  

							
		 		 	AKCEA THERAPEUTICS, INC.
				
	DATED: April 3, 2020                    	 		 	By:	 	/s/ Damien McDevitt
		 		 	Name:	 	Damien McDevitt
		 		 	Title:	 	Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]